

**IN THE CLAIMS**

1-22. (Canceled)

23. (Currently Amended) The method of Claim [[19]]26 wherein the antibody is a humanized, human or chimeric antibody.

24. (Currently Amended) The method of Claim [[19]]26, wherein said pharmaceutically acceptable carrier is saline, buffered saline or glucose in saline.

25. (Currently Amended) The method of Claim [[19]]26, wherein said pharmaceutically acceptable carrier is selected from the group consisting of solid support, liposomes and micro spheres.

26. (Currently Amended) The method of Claim 19A method of inhibiting malignant cell migration in a host having a malignancy which is melanoma by administration of a migration-inhibiting effective amount of a composition containing an anti-CCL25 antibody in a pharmaceutically acceptable carrier, wherein said antibody is administered directly to tumor tissue.

27. (Currently Amended) The method of Claim [[19]]26, wherein said antibody is administered directly to tumor bed during an invasive procedure.

28-29. (Canceled)

30. (New) The method of Claim 26, wherein said anti-CCL25 antibody is administered at a dose range of 0.01-1000 mg/kg/day.

31. (New) The method of Claim 26, wherein said anti-CCL25 antibody is administered at a dose range of 0.1-100 mg/kg/day.

32. (New) The method of Claim 25, wherein said solid support is a sponge or gauze.

33. (New) The method of Claim 23, wherein said anti-CCL25 antibody is a human antibody.

34. (New) The method of Claim 23, wherein said anti-CCL25 antibody is a humanized antibody.

35. (New) The method of Claim 23, wherein said anti-CCL25 antibody is a chimeric antibody.

36. (New) The method of Claim 24, wherein said pharmaceutically acceptable carrier is saline.

37. (New) The method of Claim 24, wherein said pharmaceutically acceptable carrier is buffered saline.

38. (New) The method of Claim 24, wherein said pharmaceutically acceptable carrier is glucose in saline.